Select Page
HubSpot Video

AMLAdvances in the understanding of Acute Myeloid Leukemia (AML) cell biology in recent years have unleashed a wave of new product development and treatment options available to patients.

This market evolution will continue to accelerate, with dozens of Phase 3 trials in progress addressing both adult and childhood AML treatment needs.

Capitalizing on our unique expertise in the AML market and in patient chart-based research, AMLsyndiTrackTM, our AML syndicated study uses real-world data to monitor the evolution of AML management.

Example of recent releases:
  • Data collected in October 21 in FR, DE, AT, CA
  • other available data from 2021 in the UK, IT, ES, BE, the NL, CH, SW...
  • over 750 interviews of Onco-Hematologists
  • over 5,600 real-world patient charts analyzed

More information about the AML syndicated study?

  • Objectives
  • Benefits
  • Samples
  • Scope
  • Types of data collected
  • Dates of research waves

Fill in the form and we will be in touch shortly.